A peek at Madrigal Pharmaceuticals Inc (MDGL): Who has invested in It?

Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) is -25.94% lower on its value in year-to-date trading and has touched a low of $119.76 and a high of $322.67 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MDGL stock was last observed hovering at around $188.54 in the last trading session, with the day’s loss setting it -17.17%.

Currently trading at $171.37, the stock is -24.05% and -23.54% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.39 million and changing -9.11% at the moment leaves the stock -18.26% off its SMA200. MDGL registered -37.68% loss for a year compared to 6-month gain of 1.56%. The firm has a 200-day simple moving average (SMA200) of -$10.18.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a -27.98% loss in the last 1 month and extending the period to 3 months gives it a 12.66%, and is -22.89% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.36% over the week and 6.76% over the month.

Madrigal Pharmaceuticals Inc (MDGL) has around 92 employees, a market worth around $3.38B and $0.00M in sales. Distance from 52-week low is 43.09% and -46.89% from its 52-week high. The company has generated returns on investments over the last 12 months (-251.15%).

Madrigal Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$5.28.The EPS is expected to shrink by -12.84% this year

297 institutions hold shares in Madrigal Pharmaceuticals Inc (MDGL), with institutional investors hold 104.92% of the company’s shares. The shares outstanding are 18.10M, and float is at 16.14M with Short Float at 20.48%. Institutions hold 94.71% of the Float.

The top institutional shareholder in the company is Baker Brothers Advisors, LLC with over 1.55 million shares valued at $356.92 million. The investor’s holdings represent 8.36% of the MDGL Shares outstanding. As of Jun 29, 2023, the second largest holder is Avoro Capital Advisors LLC with 1.52 million shares valued at $350.0 million to account for 8.20% of the shares outstanding. The other top investors are Janus Henderson Group PLC which holds 1.48 million shares representing 8.03% and valued at over $342.83 million, while Vanguard Group Inc holds 7.93% of the shares totaling 1.47 million with a market value of $338.54 million.

Madrigal Pharmaceuticals Inc (MDGL) Insider Activity

A total of 35 insider transactions have happened at Madrigal Pharmaceuticals Inc (MDGL) in the last six months, with sales accounting for 0 and purchases happening 35 times. The most recent transaction is an insider sale by Waltermire Robert E., the company’s Senior VP, Chief Pharma Dev. SEC filings show that Waltermire Robert E. sold 2,000 shares of the company’s common stock on Dec 15 at a price of $238.50 per share for a total of $0.48 million. Following the sale, the insider now owns 5667.0 shares.

Madrigal Pharmaceuticals Inc disclosed in a document filed with the SEC on Dec 14 that BAKER BROS. ADVISORS LP (Director) bought a total of 20,633 shares of the company’s common stock. The trade occurred on Dec 14 and was made at $228.32 per share for $4.71 million. Following the transaction, the insider now directly holds 1.79 million shares of the MDGL stock.

Still, SEC filings show that on Dec 14, Waltermire Robert E. (Senior VP, Chief Pharma Dev.) disposed off 2,000 shares at an average price of $232.50 for $0.47 million. The insider now directly holds 5,667 shares of Madrigal Pharmaceuticals Inc (MDGL).

Madrigal Pharmaceuticals Inc (MDGL): Who are the competitors?

One of the company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading -3.55% down over the past 12 months.Pfizer Inc. (PFE) lies in the list of competitors of the Madrigal Pharmaceuticals Inc and is -37.17% lower over the same period from MDGLDare Bioscience Inc. (DARE) is -70.25% down on the 1-year trading charts.